Stay updated with breaking news from Hans vassg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company.. ....
Oslo, April 30, 2024: Ultimovacs ASA , a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on. ....
Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of. ....
Oslo, February 8, 2023: Ultimovacs ASA , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its fourth quarter 2023 results on. ....
Oslo, 13 November 2023, Ultimovacs ASA refers to the announcement published on 9 November 2023 regarding the issuance of new shares in connection with the Company s employee incentive program. The. ....